Wednesday, June 1, 2011
Excelimmune Inc., of Woburn, Mass., closed a Series B financing worth $10.5 million to advance its antibiotic candidate Staphguard. The drug is a human recombinant polyclonal antibody designed to target methicillin-resistant Staphylococcus aureus. The funds will also be used to improve the company's discovery platform and finish proof-of-principle work on its manufacturing system.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.